Effect of the duration of macular edema on clinical outcomes in retinal vein occlusion treated with dexamethasone intravitreal implant

Ophthalmology
Wei-Shi YehJonathan W Kowalski

Abstract

To assess the effect of duration of macular edema (ME) on clinical outcomes after treatment with dexamethasone intravitreal implant 0.7 mg (Ozurdex; Allergan, Inc, Irvine, CA) in patients with ME following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). Post hoc analysis of pooled data from 2 randomized, controlled trials. Patients with vision loss resulting from ME of 6 weeks' duration or more after BRVO or CRVO (n = 690). The relationship between ME duration at the time of first treatment and treatment outcomes was assessed using logistic regression. Other factors potentially associated with ME duration or patient outcomes were adjusted for in the analyses. The proportion of patients achieving at least 15 letters improvement in best-corrected visual acuity (BCVA) or at least 200-μm or more reduction in central retinal thickness 6 or 12 months after the first treatment with dexamethasone intravitreal implant 0.7 mg. In the 6-month analysis, each 1-month increase in ME duration was associated with a significantly lower likelihood of achieving a BCVA improvement of 15 letters or more (odds ratio [OR], 0.88; 95% confidence interval [CI], 0.83-0.94; P<0.001) or a CRT reduction of 200-μm or more (OR, ...Continue Reading

Citations

Jan 1, 2013·Indian Journal of Ophthalmology·Sundaram Natarajan
May 9, 2013·International Journal of Inflammation·Avnish Deobhakta, Louis K Chang
Jan 31, 2014·Japanese Journal of Ophthalmology·Young Hee YoonUNKNOWN Korean RVO Study Group
Jul 25, 2012·Indian Journal of Ophthalmology·S Natarajan
Jun 27, 2014·Journal of Ophthalmology·Sung Uk BaekKyung Jun Choi
Dec 14, 2012·Expert Review of Clinical Pharmacology·Michael R Robinson, Scott M Whitcup
Dec 5, 2012·Ophthalmology·Gonzaga Garay-Aramburu, Javier Cabrerizo
Jun 15, 2013·Acta Ophthalmologica·Frederic MatontiStephan Pommier
Nov 22, 2013·Clinical & Experimental Optometry : Journal of the Australian Optometrical Association·Derek MacDonald
Dec 5, 2015·Journal of Ophthalmology·Mohammed Ashraf, Ahmed A R Souka
Sep 6, 2014·Expert Opinion on Pharmacotherapy·Valentina SaraoPaolo Lanzetta
Nov 1, 2013·Seminars in Ophthalmology·Irini P ChatziralliMarilita M Moschos
Jun 12, 2016·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Jean-François KorobelnikMarie-Eve Velard
Oct 6, 2012·Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift für Augenheilkunde·E MiserocchiF Bandello
Sep 28, 2017·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Chun-Ju LinYi-Yu Tsai
Jun 29, 2018·Vestnik oftalmologii·I E IoshinA M Bagirov
Apr 12, 2018·Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift für Augenheilkunde·Young Hee YoonSusan Simonyi
Feb 15, 2013·Ophthalmic Research·Giuseppe QuerquesFrancesco Bandello
Nov 3, 2017·Retina·Rekha SrinivasanUNKNOWN Sankara Nethralaya Vitreoretinal Study Group (SNVR Study Group)
Aug 9, 2019·Vestnik oftalmologii·I E IoshinA M Bagirov
Sep 10, 2015·The Cochrane Database of Systematic Reviews·Dina GewailyPaul B Greenberg
Nov 21, 2017·Retinal Cases & Brief Reports·Kapil G Kapoor, James B Colchao
Aug 21, 2020·Translational Vision Science & Technology·Eyyup KarahanTongalp H Tezel

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.